Mechanisms of action of novel cardiotonic agents

Journal of Cardiovascular Pharmacology

Volumn 40, Issue 3, 2002, Pages 323-338

  Endoh, Masao ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Ca2+ sensitizers; Cardiac excitation contraction coupling; Central mechanism; Cyclic AMP; Downstream mechanism, Levosimendan; Myofilament Ca2+ sensitivityOR 1896; Pimobendan; UD CG 212 Cl; Upstream mechanism

Indexed keywords

1,3,5,6 TETRAHYDRO 5 METHYL 6 PHENYL 3,6 METHANO 1,5 BENZODIAZOCINE 2,4 DIONE; 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 2 AMINO 5 CYANO 1,4 DIHYDRO 6 METHYL 4 (3 PHENYL 5 QUINOLINYL) 3 PYRIDINECARBOXYLIC ACID ISOPROPYL ESTER; 4 (2 CHLOROPHENYL) 1,4 DIHYDRO 2,6 DIMETHYL 5 PHENYLCARBAMOYL 3 PYRIDINECARBOXYLIC ACID 2 (2 PYRIDYL)ETHYL ESTER; 4 [2 (DIFLUOROMETHOXY)PHENYL] 1,4,5,7 TETRAHYDRO 2 METHYL 5 OXOFURO[3,4 B]PYRIDINE 3 CARBOXYLIC ACID ETHYL ESTER; 4,5 DIHYDRO 6 [4 (4 PYRIDYLAMINO)PHENYL] 3(2H) PYRIDAZINONE; 5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; 6 (3 DIMETHYLAMINOPROPIONYL)FORSKOLIN; 6 [1 [2 (4 CYANOPHENYL) 2 HYDROXYETHYL] 1,2,5,6 TETRAHYDRO 4 PYRIDYL] 4,5 DIHYDRO 3(2H) PYRIDAZINONE; ACTIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM ION; CALCIUM SENSITIZER; CARDIOTONIC AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DENOPAMINE; DIGITALIS; DIHYDROPYRIDINE DERIVATIVE; DOBUTAMINE; DOPAMINE; GINGEROL; LEVOSIMENDAN; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; N HYDROXY 5,6 DIMETHOXY 2 BENZO[B]THIOPHENECARBOXIMIDAMIDE; NORADRENALIN; O NORPIMOBENDAN; PHOSPHODIESTERASE INHIBITOR; PIMOBENDAN; TROPONIN C; TROPONIN I; UK 1745; UNCLASSIFIED DRUG; UNINDEXED DRUG; CALCIUM;

BINDING AFFINITY; CALCIUM MOBILIZATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; EXCITATION CONTRACTION COUPLING; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEMODYNAMICS; HUMAN; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; TACHYCARDIA; ANIMAL; CARDIOVASCULAR DISEASE; CLASSIFICATION; METABOLISM;

ANIMAL; CALCIUM; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; HUMAN; ANIMALS; HUMANS;

EID: 0036708252     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200209000-00001     Document Type: Review

References (152)

1. New and emerging pharmacological strategies in the management of chronic heart failure
2. Positive inotropic agents
3. Phosphodiesterase-inhibiting properties of newer inotropic agents
4. Modulation of activation of cardiac myofilaments by beta-adrenergic agonists
5. The effects of various drugs on the myocardial inotropic response
6. ++ as an inotropic mechanism
7. 2+ sensitization as mechanisms of action of physiological interventions and inotropic agents in intact myocardial cells
8. Basic pharmacology and clinical application of new positive inotropic agents
9. Regulation of myocardial contractility by a downstream mechanism
10. Calcium sensitisers: Mechanisms of action and potential usefulness as inotropes
11. β-adrenergic stimulation of calcium channels occurs by potentiation of high-activity gating modes
12. 2+ channel currents but not for the negative shift of activation
13. Phosphorylation modulates the function of the calcium release channel of sarcoplasmic reticulum from cardiac muscle
14. Phosphorylation of the sarcoplasmic reticulum and sarcolemma
15. Frequency-encoding Thr17 phospholamban phosphorylation is independent of Ser16 phosphorylation in cardiac myocytes
16. Troponin I chimera analysis of the cardiac myofilament tension response to protein kinase A
17. Cardiac myosin binding protein C
18. 2+ release during excitation-contraction coupling in cardiac myocytes
19. ++ transients
20. Modulation of L-type Ca current by denopamine, a nonparenteral partial beta 1 stimulant, in rabbit ventricular cells
21. Mechanisms of novel cardiotonic agents developed to treat the failing heart syndrome
22. Prolongation of the life span of cardiomyopathic hamster by the adrenergic beta 1-selective partial agonist denopamine
23. 1-adrenergic agonist, prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: Suppression of tumor necrosis factor-alpha production in the heart
24. Differential alteration of cardiotonic effects of EMD 57033 and β-adrenoceptor agonists in volume-overload rabbit ventricular myocytes
25. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure
26. Calcium signaling and pharmacology of cardiotonic agents
27. Amrinone reduces ischemia-reperfusion injury in rat heart
28. Beta 1- and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium
29. Diminished responsiveness to cardiac beta 1-adrenoceptor agonists in rats with chronic heart failure following myocardial infarction
30. Effects of NKH477, a water-soluble forskolin derivative, on cardiac function in rats with chronic heart failure after myocardial infarction
31. Beta-adrenergic receptor signalling in stunned myocardium of conscious pigs
32. Forskolin derivatives with increased selectivity for cardiac adenylyl cyclase
33. Cardiovascular and adenylate cyclase stimulant properties of NKH477, a novel water-soluble forskolin derivative
34. + current in ventricular myocytes
35. Effects of a new forskolin derivative, NKH477, on canine ventricular arrhythmia models
36. Profile of cardiovascular effects of NKH477, a novel forskolin derivative, assessed in isolated, blood-perfused dog heart preparations: Comparison with isoproterenol
37. Characterization of positive inotropic effect of colforsin daropate [correction of dapropate] hydrochloride, a water-soluble forskolin derivative, in isolated adult rat cardiomyocytes
38. Improvement of drug-induced cardiac failure by NKH477, a novel forskolin derivative, in the dog heart-lung preparation
39. Zatebradine attenuates cAMP-related positive chronotropic but not inotropic responses in isolated, perfused right atria of the dog
40. Clinical effects of β-adrenergic blockade in chronic heart failure: A metaanalysis of double-blind, placebo-controlled, randomized trials
41. Effectiveness of carvedilol alone versus carvedilol + pimobendan for severe congestive heart failure
42. Inotropes in the beta-blocker era
43. Pharmacological characterization of effects of UK-1745, a novel cardiotonic agent with β-adrenoceptor-blocking action, in aequorin-loaded canine right ventricular muscle
44. 2+ channels
45. 2+ channels
46. Possible functional linkage between the cardiac dihydropyridine and ryanodine receptor: Acceleration of rest decay by Bay K 8644
47. Bay K 8644 increases resting calcium spark frequency in ferret ventricular myocytes
48. 2+ spark frequency in ferret ventricular myocytes independent of Ca influx: Contrast with caffeine and ryanodine effects
49. 2+ cross signaling between DHP and ryanodine receptors in rat ventricular myocytes
50. Activation of purified cardiac ryanodine receptors by dihydropyridine agonists
51. Application of physiologically active substances isolated from natural resources to pharmacological studies
52. 2+-pumping ATPase in skeletal and cardiac sarcoplasmic reticulum
53. ++-pumping adenosine triphosphatase of sarcoplasmic reticulum, in guinea pig atrial muscle
54. Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure
55. Gingerol, isoproterenol and ouabain normalize impaired post-rest behavior but not force-frequency relation in failing human myocardium
56. Effects of caffeine on Ca-activated force production in skinned cardiac and skeletal muscle fibers of the rat
57. 2+-specific sites of cardiac troponin and troponin C
58. Localization of regions of troponin I important in deactivation of cardiac myofilaments by acidic pH
59. Dynamic interaction between cardiac myosin isoforms modifies velocity of actomyosin sliding in vitro
60. Stereoselective actions of thiadiazinones on canine cardiac myocytes and myofilaments
61. Troponin and tropomyosin: Proteins that switch on and tune in the activity of cardiac myofilaments
62. 2+-activated myofilament tension in adult cardiac myocytes
63. 2+ sensitizer EMD 57033 and cardiac troponin I inhibitory peptide
64. 2+ concentration in mammalian cardiac muscles
65. 2+ mediated through α- and β-adrenoceptors
66. Dual inhibition of myocardial function through muscarinic and adenosine receptors in the mammalian heart
67. 2+ transients in aequorin-loaded right-ventricular papillary muscles and indo-1-loaded single ventricular cardiomyocytes of the rabbit
68. Differential effects of sulmazole (AR-L 115 BS) on contractile force and cyclic AMP levels in canine ventricular muscle: Comparison with MDL 17,043
69. 2+ sensitizing effect of (+)-enantiomer EMD 57033 on diastolic function but not on systolic function in rabbit ventricular cardiomyocytes
70. Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium
71. 2+ sensitizer Org 30029 reverses acidosis- and BDM-induced contractile depression in canine myocardium
72. Positive inotropic effects of the calcium sensitizer CGP 48506 in guinea pig myocardium
73. Positive inotropic effects of the calcium sensitizer CGP 48506 in failing human myocardium
74. Does the positive inotropic action of a novel cardiotonic agent, MCI-154, involve mechanisms other than cyclic AMP?
75. Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 Cl in canine ventricular myocardium
76. Mechanisms of the contractile effects of levosimendan in the mammalian heart
77. Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium
78. Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium
79. 2+ sensitivity induced by UD-CG 212 Cl, an active metabolite of pimobendan, in canine ventricular myocardium
80. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle
81. The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan
82. Tuning the human heart molecular motors by myosin light chains
83. Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation
84. ++ sensitizer with no chronotropic activity in mammalian cardiac muscle
85. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan
86. ++ sensitizers impair cardiac relaxation in failing human myocardium
87. EMD 53998 sensitizes the contractile proteins to calcium in intact ferret ventricular muscle
88. Differential effects of EMD-53998 on calcium-pressure relationship in normal and ischemic guinea pig heart
89. Effects of EMD 57033 on contraction and relaxation in isolated rabbit hearts
90. Functional effects of EMD-57033 in isovolumically beating isolated rabbit hearts
91. In vivo evidence of positive inotropism of EMD 57033 through calcium sensitization
92. Enantiomeric dissection of the effects of the inotropic agent, EMD 53998, in single cardiac myocytes
93. Positive inotropic effects of calcium sensitizers on normal and failing cardiac myocytes
94. A novel thiadiazinone derivative fully reverses acidosis-induced depression of force in cardiac muscle by a calcium-sensitizing effect
95. Calcium sensitization with pimobendan: Pharmacology, haemodynamic improvement, and sudden death in patients with chronic congestive heart failure
96. 2+ activation and the inotropic effect of pimobendan: Comparison with milrinone
97. Pimobendan increases calcium sensitivity of skinned human papillary muscle fibers
98. Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium
99. UD-CG 115: A cardiotonic pyridazinone which elevates cyclic AMP and prolongs the action potential in guinea-pig papillary muscle
100. Pimobendan directly sensitizes reconstituted thin filament to slide on cardiac myosin
101. 2+ current and developed tension in guinea-pig ventricular myocytes and papillary muscle: Comparison with IBMX, milrinone, and cilostazol
102. The cardiac effects of pimobendan (but not amrinone) are preserved at rest and during exercise in conscious dogs with pacing-induced heart failure
103. Effect of pimobendan on exercise capacity in patients with heart failure: Main results from the Pimobendan in Congestive Heart Failure (PICO) trial
104. Acute effects of a single low oral dose of pimobendan on left ventricular systolic and diastolic function in patients with congestive heart failure
105. 2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart
106. Further evidence for the cardiac troponin C mediated calcium sensitization by levosimendan: Structure-response and binding analysis with analogs of levosimendan
107. Troponin C-mediated calcium sensitization by levosimendan accelerates the proportional development of isometric tension
108. Drug binding to cardiac troponin C
109. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium
110. + channel in rat ventricular cells
111. + channel in rat arterial myocytes
112. Levosimendan: Effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart
113. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure
114. ++ sensitivity of the contractile system by MCI-154, a novel cardiotonic agent, in chemically skinned fibers from the guinea pig papillary muscles
115. 2+ sensitivity of reconstituted thin filament: A study using a novel in vitro motility assay technique
116. Restoration of ischemic contractile failure of indo-1-loaded guinea pig heart by a calcium sensitizer, MCI-154
117. Inotropic and lusitropic effects of MCI-154 (6-[4-(4-pyridyl)aminophenyl]-4,5-dihydro-3(2H)-pyridazinone) on human myocardium
118. 2+ activation of skinned human myocardium
119. ++-regulated interactions between troponin subunits from bovine heart
120. ++ binding by MCI-154, a novel cardiotonic agent
121. High selectivity for inhibition of phosphodiesterase III and positive inotropic effects of MCI-154 in guinea pig myocardium
122. Calcium sensitization in perfused beating guinea pig heart by a positive inotropic agent MCI-154
123. 2+ sensitizer, decreases the oxygen cost of contractility in isolated canine hearts
124. 2+ sensitizer, MCI-154, on the myocardial oxygen consumption-cardiac output relation in patients with left ventricular dysfunction after myocardial infarction: Comparison with dobutamine and phosphodiesterase inhibitor
125. Effects of MCI-154, a calcium sensitizer, on left ventricular systolic and diastolic function in pacing-induced heart failure in the dog
126. 2+ sensitization with a new cardiotonic agent, MCI-154, on diseased human hearts
127. The two mechanisms of action of racemic cardiotonic EMD 53998, calcium sensitization and phosphodiesterase inhibition, reside in different enantiomers
128. Functional and energetic effects of the inotropic agents EMD-57033 and BAPTA on the isolated rat heart
129. Economy of contraction of cardiomyocytes as influenced by different positive inotropic interventions
130. 5-Methyl-6-phenyl-1,3,5,6-tetrahydro-3,6-methano-1,5-benzodiazocine- 2,4-dione (BA 41899): Representative of a novel class of purely calcium-sensitizing agents
131. CGP-48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction
132. 2+ sensitizing agent, and (+)-5-(1-(3,4-dimethoxybenzoyl)-1,2,3,4-tetrahydroquinolin-6-yl)-6-methyl-3
133. 2+ sensitizers EMD 57033 and CGP 48506 on cross-bridge cycling in human myocardium
134. 2+-independent mechanisms in porcine skinned trabeculae
135. 2+ sensitizers caffeine and CGP 48506 on the relaxation rate of rat skinned cardiac trabeculae
136. Overall cardiac functional effect of positive inotropic drugs with differing effects on relaxation
137. Relaxation effect of CGP-48506, EMD-57033, and dobutamine in ejecting and isovolumically beating rabbit hearts
138. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure?
139. Org 30029: A new cardiotonic agent possessing both phosphodiesterase inhibitory and calcium-sensitizing properties
140. The "calcium sensitising" effects of ORG30029 in saponin- or Triton-skinned rat cardiac muscle
141. Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: Positive inotropic and phosphodiesterase inhibitory effects of Org 30029, milrinone and rolipram
142. Comparison of the effects of ORG 30029, dobutamine and high perfusate calcium on function and metabolism in rat heart
143. ++ sensitizing action. 3rd communication: Stereoselectivity of the enantiomers in cardiovascular effects
144. ++ sensitizing action. 2nd communication: In vivo cardiovascular effects and bioavailability in dogs
145. ++ sensitizing action. 1st communication: Phosphodiesterase III inhibitory effect and class III antiarrhythmic effect in guinea-pig heart
146. The positive inotropic calcium sensitizer EMD 53998 antagonizes phosphate action on cross-bridges in cardiac skinned fibers
147. Relation of positive inotropic and chronotropic effects of pimobendan, UD-CG 212 Cl, milrinone and other phosphodiesterase inhibitors to phosphodiesterase III inhibition in guinea-pig heart
148. Biochemical mechanisms of the novel cardiotonic agent OR-1259
149. Phosphodiesterase III inhibition by MCI-154 and other cardiotonic drugs in relation to force of contraction, cAMP content and calcium sensitization in the heart
150. The effect of digoxin on mortality and morbidity in patients with heart failure
151. Effect of oral milrinone on mortality in severe heart failure